Apogee Therapeutics Prices $350M Public Offering at $70.00/Share Following Positive Clinical Data
APGE has more than doubled off its 52-week low of $26.2 on elevated volume (3.3× avg).
Summary
Apogee Therapeutics has priced its underwritten public offering of 5 million shares at $70.00 per share, raising $350 million in gross proceeds, following recent positive Phase 2 clinical trial data.
Key Events · Financing and Capital Events · APGE
-
Public Offering Priced
Apogee Therapeutics priced its underwritten public offering of 5,000,000 shares of common stock at $70.00 per share, totaling $350 million in gross proceeds.
-
Net Proceeds to Company
The company expects to receive net proceeds of approximately $329 million from the offering, or $378.35 million if the underwriters fully exercise their option to purchase an additional 750,000 shares.
-
Strategic Capital Raise
This offering follows the announcement of highly positive 52-week maintenance data from Part A of its Phase 2 APEX clinical trial for zumilokibart on March 23, 2026, indicating a strategic move to capitalize on positive news.
-
Use of Proceeds
Proceeds will be used to fund preclinical studies, clinical trials, manufacturing, commercial readiness activities for antibody programs, and for general corporate purposes, extending the company's operational runway into the first quarter of 2029.
Analysis · APGE · Life Sciences
This 424B5 filing finalizes the terms and pricing of the public offering initiated on March 23, 2026, securing substantial capital for Apogee Therapeutics. The offering, priced at a modest discount to the previous day's closing price, strategically follows the announcement of positive 52-week Phase 2 clinical trial data for its lead candidate, zumilokibart. This capital raise significantly bolsters the company's cash position, extending its operational runway well into 2029 and providing crucial funding for ongoing preclinical studies, clinical trials, manufacturing, and general corporate purposes. While dilutive for existing shareholders, the successful execution of this offering at a favorable time demonstrates investor confidence and provides the financial stability needed to advance its pipeline.
At the time of this filing, APGE was trading at $78.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5B. The 52-week trading range was $26.20 to $85.04. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.